Abstract
A new cancer gene, HIC-1 (Hypermethylated in Cancer) telomeric to p53 on chromosome 17p may be of clinical importance in sporadic breast cancer. Regional DNA hypermethylation of 17p13.3 resulting in suppression of gene expression has been shown to precede 17p structural changes in human carcinogenesis. In addition, loss of heterozygosity studies have suggested clinically significant involvement of a gene on 17p13.3 associated with poor prognosis in breast cancer. Using RT-PCR analysis, we demonstrate that the MCF7 (wild type p53) cell line expressed HIC-1 transcripts but the MDAMB231 (mutant p53) cell line did not, suggesting loss of HIC-1 expression and p53 malfunction may be synergistic events in sporadic breast cancer. HIC-1 expression was examined using RT-PCR on RNA extracted from 50 primary untreated, human breast cancers and was detected in only 7/50 (14%) cancers. All seven patients with HIC-1 expression were alive without disease recurrence after 8 years follow-up and 5/7 had detectable p53 wild type mRNA expression. This suggests that retained HIC-1 expression may offer a survival advantage. However the seven cancers had 17p13.3 loss of heterozygosity (LOH; four patients), a feature previously associated with poor prognosis, or were homozygous (three patients) suggesting there may be two genes at 17p13.3 involved in breast carcinogenesis. Using a demethylating drug 5-aza-2′-deoxycytidine (DeoxyC), HIC-1 expression was restored in the MDAMB231 cells, also suggesting restoration of HIC-1 function by reversing HIC-1 hypermethylation may offer a therapeutic avenue in breast cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Abbreviations
- HIC-1 :
-
hypermethylated in cancer gene 1
- DNA:
-
Deoxyribonucleic acid
- mRNA:
-
messenger ribonucleic acid
- RT-PCR:
-
reverse transcription-polymerase chain reaction
- LOH:
-
loss of heterozygosity
- DeoxyC:
-
5-aza-2′-deoxycytidine
References
Aldaz CM, Chen T, Sahin A, Cunningham J and Bondy M (1995) Comparitive allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 55: 3976–3981
Carter MG, Johns MA, Zeng X, Zhou L, Zink MC, Mankowski JL, Donovan DM and Baylin SB (2000) Mice deficient in the candidate tumor suppressor gene Hicl exhibit developmental defects of structures affected in the Miller-Dieker syndrome. Hum Mol Genet 9: 413–419
Casey G, Plummer S, Hoeltge G, Scanlon D, Fasching C and Stanbridge EJ (1993) Functional evidence for a breast cancer suppresor gene on shromosome 17. Hum Mol Genet 2: 1921–1927
Coles C, Thompson AM, Elder PA, Cohen BB, MacKenzie IM, Cranston G, Chetty U, Mackay J, Macdonald M, Nakamura Y, Hoyheim B and Steele CM (1990) Evidence implicating at least two genes on chromosome 17 p in breast carcinogenesis. Lancet 336: 761–763
Cornelis RS, van Vliet M, Vos CB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, Khan PM, Borresen AL, Cornelisse CJ and Devilee P (1994) Evidence for a gene on 17 p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res 54: 4200–4206
Cross SH, Charlton JA, Nan X and Bird AP (1994) Purification of CpG islands using a methylated DNA binding column. Nature 6: 236–244
Deltour S, Guerardel C, Stehelin D and Leprince D (1993) the carboxy-terminal end of the candidate tumor suppressor gene HIC-1 is phylogenetically conserved. Biochim Biophys Acta 1443: 230–232
Fujii H, Biel M, Zhou W, Weitzman S, Baylin SB and Gabrielson E (1998) Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene 16: 2159–2164
Guerardel C, Deltour S and Leprince D (1999) Evolutionary divergence in the broad complex tramtrak and bric a brac/poxviruses and zinc finger domain from the candidate tumor suppressor gene hypermethylated in cancer. FEBS Lett 451: 253–256
Issa JP, Baylin SB and Herman JG (1997) DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 11(Suppl 1): S7–S11
Li Q, Jedlicka A, Ahuja N, Gibbons MC, Baylin SB, Burger PC and Issa JP (1998) Concordant methylation of the ER and N33 genes in glioblastoma multiforme. Oncogene 16: 3197–3202
Liscia D, Morizio R, Venesio T, Palenzona C, Donadio M and Callahan R (1999) Prognostic significance of loss of heterozygosity at loci on chromosome 17 p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene. Br J Cancer 80: 821–826
Makos M, Nelkin BD, Chazin VR, Cavenee WK, Brodeur GM and Baylin SB (1993) Regional DNA hypermethylation at D17S5 precedes 17 p structural changes in the progression of renal tumors. Cancer Res 53: 2719–2722
Makos-Wales M, Biel MA, el Deiry W, Nelkin BD, Issa J-P, Cavanee WK, Kuerbitz SJ and Baylin SB (1995) P53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17 p13.3. Nature Medicine 1: 570–577
Melki JR, Vincent PC and Clark SJ (1993) Cancer-specific region of hypermethylation identified within the HIC-1 putative tumour suppressor gene in acute myeloid leukaemia. Leukaemia 6: 877–883
Nagai MA, Medeiros AC, Brentani MM, Marques LA, Mazoyer S and Mulligan LM (1995) Five distinct deleted regions on chromosome 17 defining different subsets of human primary breast tumours. Oncolgy 52: 448–453
O’Neill M, Campbell SJ, Save V, Thompson AM and Hall PA (1998) An immunochemical analysis of mdm2 expression in human breast cancer and the identification of a growth-regulated cross-reacting species p170. J Pathol 186: 254–261
Phelan CM, Borg A, Cuny M and Crichton DN 22 others (1998) Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res 58: 1004–1012
Phillips NJ, Ziegler MR, Radford DM, Fair KL, Steinbeck T, Xynos FP and Donis-Keller H (1996) Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Cancer Res 56: 606–611
Stack M, Jones D, White G, Liscia D, Venesio T, Casey G, Crichton D, Varley J, Mitchell E, Heighway J and Santibanez-Koref M (1995) Detailed mapping and loss of heterozygosity analysis suggests a suppressor locus involved in sporadic breast cancer within the distal region of chromosome band 17p13.3. Human Molecular Genetics 4: 2047–2055
Steele RJC, Thompson AM, Hall PA and Lane DP (1998) The p53 tumour suppressor gene. Br J Surg 85: 1460–1467
Theile M, Hartmann S, Scherthan H, Arnold W, Deppert W, Frege R, Glabb F, Haensch W and Scherneck S (1995) Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes. Oncogene 10: 439–447
Thompson AM, Steel CM, Chetty U, Hawkins RA, Miller WR, Carter DC, Forrest APM and Evans H (1990) p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer 61: 74–78
Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, Evans HJ and Steel CM (1992) P53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 50: 528–532
Thompson AM, Crichton DN, Elton RA, Clay MF, Chetty U and Steel CM (1998) Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium term follow up. Br J Cancer 77: 797–800
Ziyaie D, Hupp TR and Thompson AM (2000) p53 and breast cancer. The Breast 9: 239–246
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Nicoll, G., Crichton, D., McDowell, H. et al. Expression of the hypermethylated in cancer gene (HIC-1) is associated with good outcome in human breast cancer. Br J Cancer 85, 1878–1882 (2001). https://doi.org/10.1054/bjoc.2001.2163
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2163
Keywords
This article is cited by
-
Downregulation of hypermethylated in cancer-1 by miR-4532 promotes adriamycin resistance in breast cancer cells
Cancer Cell International (2018)
-
Zinc finger protein ZBTB20 expression is increased in hepatocellular carcinoma and associated with poor prognosis
BMC Cancer (2011)
-
CpG-island methylation study of liver fluke-related cholangiocarcinoma
British Journal of Cancer (2011)
-
Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines
BMC Cancer (2010)
-
Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control
Oncogene (2009)